Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15337535 | 0.93 | REN (0.46) | RENCYP2C9CHRM2HTR1AADRA2A | |
| SCHEMBL89417 | 0.83 | REN (0.59) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL15087927 | 0.82 | REN (0.56) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL89400 | 0.82 | REN (0.62) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL3072690 | 0.81 | REN (0.55) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL78623 | 0.81 | REN (0.55) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL2808804 | 0.81 | REN (0.55) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL2811094 | 0.81 | REN (0.55) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL90610 | 0.81 | REN (0.55) | RENCYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL13434190 | 0.80 | REN (0.56) | RENCYP2C9CYP2D6CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420491-B1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | REN 1/4885CYP2C9 214/4885CYP2D6 479/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | REN 1/4885CYP2C9 211/4885CYP2D6 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.